APA (7th ed.) Citation

AF, D., LL, H., K, N., L, F., JC, I., K, M., . . . AC, S. (2025). Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV in South Africa: An observer-blinded, randomised, controlled, phase 2 trial. The lancet. HIV, 12(8), e546. https://doi.org/10.1016/S2352-3018(25)00124-9

Chicago Style (17th ed.) Citation

AF, Dagnew, et al. "Safety and Immunogenicity of Investigational Tuberculosis Vaccine M72/AS01E-4 in People Living with HIV in South Africa: An Observer-blinded, Randomised, Controlled, Phase 2 Trial." The Lancet. HIV 12, no. 8 (2025): e546. https://doi.org/10.1016/S2352-3018(25)00124-9.

MLA (9th ed.) Citation

AF, Dagnew, et al. "Safety and Immunogenicity of Investigational Tuberculosis Vaccine M72/AS01E-4 in People Living with HIV in South Africa: An Observer-blinded, Randomised, Controlled, Phase 2 Trial." The Lancet. HIV, vol. 12, no. 8, 2025, p. e546, https://doi.org/10.1016/S2352-3018(25)00124-9.